Lionhunter Capital Management’s Viridian Therapeutics VRDN Stock Holding History
Bought
Maintained
Sold
Other funds holding VRDN
Lionhunter Capital Management's VRDN Position: Q3 2026 in Review
Lionhunter Capital Management opened a new position in Viridian Therapeutics (VRDN) in Q3 2026: 110,000 shares worth $2.26M. The stake represents 1.01% of the portfolio and ranks #34 among its holdings.
154 funds tracked by Wall St. Rank hold VRDN as of Q3 2026.
- Lionhunter Capital Management held 110,000 shares of Viridian Therapeutics worth $2.26M as of Q3 2026.
- Viridian Therapeutics was a new Lionhunter Capital Management position in Q3 2026.
- Viridian Therapeutics made up 1.01% of Lionhunter Capital Management's portfolio in Q3 2026, its #34 holding.
- 154 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2026.
Based on Lionhunter Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.